Ticker Details
CytomX Therapeutics, Inc. CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is engaged in developing antibody therapeutics based on probody technology platform.
IPO Date:	October 8, 2015
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$920.03M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.24 | 3.02%
Avg Daily Range (30 D):	$0.20 | 3.82%
Avg Daily Range (90 D):	$0.16 | 3.65%

Institutional Daily Volume
Avg Daily Volume:	.99M
Avg Daily Volume (30 D):	3.24M
Avg Daily Volume (90 D):	2.85M

Trade Size
Avg Trade Size (Sh.):	200
Avg Trade Size (Sh.) (30 D):	151
Avg Trade Size (Sh.) (90 D):	162

Institutional Trades
Total Institutional Trades:	1,021
Avg Institutional Trade:	$1.46M
Avg Institutional Trade (30 D):	$1.65M
Avg Institutional Trade (90 D):	$1.82M
Avg Institutional Trade Volume:	.22M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.61M
Avg Closing Trade (30 D):	$1.13M
Avg Closing Trade (90 D):	$1.75M
Avg Closing Volume:	210.31K

News

Feb 4, 2026 @ 1:00 PM CytomX Therapeutics to Present at Upcoming Februar... Source: Not Specified

Nov 13, 2025 @ 1:00 PM CytomX Therapeutics to Present at the Jefferies Lo... Source: Cytomx Therapeutics

Oct 30, 2025 @ 12:00 PM CytomX Therapeutics to Report Third Quarter 2025 F... Source: Cytomx Therapeutics

Sep 25, 2025 @ 9:06 PM 12 Health Care Stocks Moving In Thursday's After-M... Source: Benzinga Staff Writer

Aug 7, 2025 @ 10:29 PM CytomX (CTMX) Q2 Revenue Drops 26% Source: Na

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS
Diluted EPS
Revenue	$113.63M	$5.96M	$18.66M
Gross Profit
Net Income / Loss	$28.02M	$-14.23M	$-.15M
Operating Income / Loss	$23.25M	$-15.77M	$-1.29M
Cost of Revenue
Net Cash Flow	$-6.39M	$-14.86M	$10.99M
PE Ratio